Corvus Pharmaceuticals, Inc. CRVS
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Corvus Pharmaceuticals, Inc. (CRVS) is a healthcare company listed in the US with a market value of about $898M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -61%.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. It was profitable in 0 of the last 10 years in our data. Its share count rose by 71% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$15M | -$62M | -$27M | -$41M | -$43M | -$6M | -$47M | -$47M | -$56M | -$36M |
| Free cash flow | -$33M | — | -$24M | -$27M | -$37M | -$35M | -$37M | -$41M | -$46M | -$30M |
| EPS (diluted) | $-0.53 | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.20 | $-1.59 | $-1.71 | $-2.72 | $-2.36 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -69.2% | -81.8% | -58.4% | -55.5% | -38.3% | -58.8% | -65.8% | -44.6% | -66.6% | -27.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $31.50, 196% above the current price; targets range from $27.00 to $42.00; the consensus rating is “Strong buy”; expected EPS is $-0.80 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Corvus Pharmaceuticals pay a dividend?
Not currently.
Is Corvus Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Corvus Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.